AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 72 min read$JNJ

Duato Joaquin sold $12.5M of JNJ

Duato Joaquin (CEO and Chairman of the Board) sold 48,480 shares of JOHNSON & JOHNSON (JNJ) at an average of $258.15 ($258.06–$258.74, $12.52M total) across 2 trades on 2026-08-05.

Original reporting
SEC EDGAR · Duato Joaquin
Published Aug 7, 2026, 9:50 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 9:56 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$JNJ
Neutral
medium confidence
Mentioned
$JNJ
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$JNJNeutralLow
01

Why it matters

The newest fact is the quantified open-market sale by the CEO and Chairman, including trade dates, share count, and total value.

02

Market read

Traders may monitor insider activity for sentiment, but this filing alone does not change the company’s fundamentals.

03

What to watch

Form 4 does not reveal whether additional sales or purchases occurred around the same period, nor does it indicate whether the executive retained exposure via options or other vehicles.

Relevance 7/10Novelty 5/10Timing: filed 2026-08-07, trades dated 2026-08-05

Background

The article is an SEC Form 4 insider transaction disclosure for Johnson & Johnson.

Company-level read

Ticker impact

$JNJNeutralMedium confidence
Context

SEC Form 4 shows CEO and Chairman Duato Joaquin sold 48,480 shares of JNJ in open-market trades totaling about $12.5M on 2026-08-05.

Expected impact

Likely limited, short-lived sentiment impact; no direct signal on earnings or guidance from the filing alone.

Evidence & confidence

The filing is a primary-source Form 4 and quantifies the sale size and timing, but it provides no new operational or financial information and notes no 10b5-1 plan.

Market effects

Sector

Insider selling at a mega-cap healthcare name can marginally influence sentiment across large-cap pharma/medtech, but no sector-specific catalyst is provided.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The absence of a stated 10b5-1 plan does not necessarily imply negative fundamentals; sales can be driven by diversification, taxes, or pre-planned personal liquidity needs.

Key entities

  • issuer
    Johnson & Johnson

    Subject of the Form 4 insider sale disclosure.

  • insider
    Duato Joaquin

    CEO and Chairman of the Board who sold shares in open-market transactions.

Read at source← All news

Related articles

AUG 4
$JNJMedAI 8/10

Mary Alexander Applauds Historic Johnson & Johnson Talc Settlement, Calling It a Long-Overdue Measure of Justice for Thousands of Women

Attorney Mary Alexander said a proposed minimum $5.5 billion talc settlement involving Johnson & Johnson could compensate tens of thousands of plaintiffs alleging ovarian cancer from J&J talc-based products. Alexander’s firm represents affected women and families, and said J&J denies liability. The settlement follows years of litigation and appeals, with J&J previously seeking bankruptcy resolution.

prnewswire.com2 min
AUG 2
$JNJMedAI 9/10

Johnson & Johnson Secures $2.58 Billion Option To Acquire Sail Biomedicines

Johnson & Johnson agreed with Sail Biomedicines to develop in vivo CAR-T therapies for immune-mediated diseases and secured an exclusive option to acquire Sail for $2.58 billion. J&J will make $785 million in initial payments, including a $465 million equity investment, plus up to $140 million in milestone payments. J&J expects EPS impact of about -$0.18 in 2026 and -$1.28 in 2027, subject to approvals.

pulse2.com4 min
JUL 31
$JNJMedAI 8/10

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline - Johnson & Johnson

Johnson & Johnson said it will buy Firefly Bio Inc. for $1 billion in cash and partner with Sail Biomedicines, including a $2.58 billion option purchase. The Sail deal includes $785 million upfront and $140 million in development milestones. J&J expects about a $1 billion in-process R&D charge in Q3 2026 and a roughly $0.46 adjusted EPS hit in 2026. JNJ shares were up 0.86% to $258.03.

benzinga.com5 min
JUL 31
$JNJMedAI 8/10

Johnson & Johnson Offers $5.5B to Settle Talc Cancer Lawsuits

Johnson & Johnson (J&J) agreed to a proposed $5.5 billion settlement to resolve about 76,000 talc ovarian cancer lawsuits tied to products including Johnson’s Baby Powder, with total payout potentially exceeding $7 billion if at least 95% of eligible claimants opt in. J&J denies wrongdoing and expects up to $3 billion in 2027, then payments from 2028.

92q.com4 min